A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program (SURMOUNT-3)

I8F-MC-GPHM -

This is a study of tirzepatide in participants with obesity (overweight). The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Obesity
What the trial is testing?
Tirzepatide
Could I receive a Placebo?
Yes
Enrollment Goal
806
Trial Dates
Mar 29, 2021 - May 12, 2023
How long will I be in the trial?
The study will last about 90 weeks and may include up to 29 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have a body mass index (BMI) 30 kg/m² or 27 kg/m²

  • Participants must be previously diagnosed with at least 1 of the following high blood pressure, high cholesterol, sleep apnea or heart disease

Participants Must Not:

  • Participants must not have type 1 diabetes or type 2 diabetes

  • Participant must not have been taking weight loss drugs, including over-the-counter medications during the last 3 months

  • Participants must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months

  • Participants must not have pancreatitis

  • Participants must not have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources